BioStock: CombiGene’s pain programme takes important steps forward

CombiGene is moving towards the toxicological studies in the COZY01 pain project, which is being conducted in collaboration with the Danish biotech company Zyneyro.  
– We will continue to work methodically to complete the preclinical studies needed in order to be able to start the preclinical toxicology programme, says CombiGene’s CEO Peter Ekolind.

Read the full interview with Peter Ekolind at biostock.se:

https://www.biostock.se/en/2024/05/combigenes-pain-programme-takes-important-steps-forward/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/